2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2275

Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2113

Familial Mediterranean Fever in Chinese Adult Patients

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2016

Favourable Changes in Power Doppler Scores in the Feet over 1-Year in an Early Rheumatoid Arthritis Cohort: The Role of Rheumatoid Factor and Anti–Citrullinated Protein Antibody

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2199

Feasibility of a Novel Approach to Studying Early Knee Osteoarthritis: An Offspring Study

Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies

9:00AM-11:00AM: Abstract Number: 1928

Fibroblast-like Synovial Cell Production of ED-a Fibronectin Contributes to Inflammation in Osteoarthritis

Biology and Pathology of Bone and Joint Poster II

9:00AM-11:00AM: Abstract Number: 1973

Fibromyalgia in Real Life a National French Web-Based Survey in 4516 Patients

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 1991

Fibromyalgia in Russian Refugees: Translation and Validation of the Revised Symptom Impact Questionnaire

ARHP Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

9:00AM-11:00AM: Abstract Number: 2012

First Description of Tenosynovitis Prevalence in a Large Cohort of ACPA-Positive Patients

Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2062

Flow-Mediated Dilation As a Marker of Endothelial Dysfunction in Gout

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2430

For Each HLA-DRB1 Genotype, the Likelihood to Develop RA Correlates with the Probability of Binding at Least a Peptide from PAD4

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2749

Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2700

Fra-2 Overexpression Leads to Systemic Autoimmunity By Affecting IL2 Dependent Treg Homeostasis

T Cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 2383

Frailty and Risk of Fractures in Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2307

Frequency of Comorbidities in Patients with Juvenile Ideopathic Arthritis – Results of an Observational Cohort Study

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2594

Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].